Apr. 2 at 4:37 PM
$LUNG
As of now no official announcement regarding an acquisition of Pulmonx (LUNG).
However, the company is currently at the center of intense M&A (mergers and acquisitions) speculation due to its depressed valuation and its unique, FDA-approved Zephyr Valve technology.Here is the "consensus" on who might buy Pulmonx and why the rumors are heating up right now.
The "Why Now?" (The 2026 Context)Pulmonx is currently in a "reset" phase. After a rocky 2025 where U.S. sales stumbled, the company brought back its former CEO, Glen French, to steer a turnaround.The Discount: As of March 2026, the stock has been trading at a Price-to-Sales (P/S) ratio of roughly 0.7x, while the industry average is closer to 3.1x. This makes them a "bargain-bin" target for a larger player.The Runway: They recently secured a
$60 million credit facility, extending their debt maturity to 2031. This "cleans up the kitchen" for a potential buyer by ensuring the company isn't in immediate financial distress.
